IRF9 and neuroblastoma: Recent pan‐cancer analyses have demonstrated that PTBPs are prognostic biomarkers associated with immunomodulation.[49] It has also been shown that PTBP2 has no significant effect on neuroblastoma cell viability, whereas PTBP2‐mediated alternative splicing of IRF9 facilitates immune compartmentalization in neuroblastoma.[50] Therefore, it is reasonable to hypothesize that PTBP3 contributes to gallbladder cancer progression by affecting the tumor microenvironment.